M&A - Mosaic ImmunoEngineering Inc.

Form Type: 10-K

Filing Date: 2025-04-15

Corporate Action: Acquisition

Type: Update

Accession Number: 000168316825002584

Filing Summary: Mosaic ImmunoEngineering, Inc. is actively pursuing an acquisition of rights to certain technologies from Oncotelic Therapeutics, Inc., specifically clinical stage necroptosis cancer therapies and proprietary AI technologies. This acquisition is part of their strategy to build a product pipeline focused on immunotherapy treatments. The arrangement includes terms for equity transactions valued at approximately $15 million, subject to shareholder approval and other conditions, including waivers from holders of Convertible Notes. If the requisite approvals are not achieved by June 30, 2025, the company may face operational cessation. The report outlines significant financial risks, including the necessity of securing additional capital to continue operations and the potential for substantial dilution to current shareholders. The company currently has no development pipeline and acknowledges the risks associated with dependence on third-party collaborations, making investor support critical for future viability. Additionally, various operational and financial uncertainties are discussed, stressing the speculative nature of investments in the company.

Form Type: 8-K

Filing Date: 2025-01-02

Corporate Action: Acquisition

Type: Update

Accession Number: 000168316825000009

Filing Summary: Mosaic ImmunoEngineering, Inc. has extended the expiration date of its binding term sheet with Oncotelic Therapeutics, Inc. to June 30, 2025. The binding term sheet was initially entered into on April 26, 2024, and involves the acquisition of certain rights to technologies from Oncotelic, including their clinical stage necroptosis cancer therapies and proprietary AI technologies for identifying immunotherapy combinations. In exchange for these rights, Mosaic plans to issue Oncotelic shares valued at $15 million upon the execution of a definitive agreement, with potential additional shares worth up to $15 million contingent on milestones. The parties are negotiating the definitive agreement, but no guarantees for a transaction have been established.